These data offer the first mechanistic link between the two major categories of human genetically triggered aortic aneurysm (TGFβVs and SMCVs), and have therapeutic implications for treatment of not only aortic aneurysm, but also other HDAC9-associated human vascular diseases involving VSMC function, including hypertension17, intracranial aneurysms18, ischemic stroke19, and myocardial infarction20. This evidence concerns the gene HDAC9 and aortic aneurysm.